Map the US route before you spend a euro on it. A planner for European founders in brain health and digital health: what FDA expects, who pays, who buys, which laws apply and what to set up.
The principle
A European start-up usually plans the US around FDA. FDA decides whether you may market a claim. It says nothing about who pays for it, who buys it, which privacy and AI laws apply or which US entity signs the contract. Each of those has its own owner, its own clock and its own proof.
Landfall splits the route into five gates and shows the one that sets your pace. The route depends on what you claim, because the claim decides the FDA path, the payer and the legal exposure at once.
Pear Therapeutics held FDA authorization for its prescription digital therapeutics and filed for Chapter 11 in 2023. Authorization without a payer does not make revenue.
Route planner
Three answers produce a route. Two optional steps sharpen the payer and the checklist. Nothing you enter leaves your browser.
1What do you claim in the US? The claim sets the FDA path.
2What is the product?
3Which condition area?
4Who do you think pays first? Optional. Pick up to two.
5Where are you today? Optional. Tick what applies.
Answer the first three questions to see your route.
The claim ladder
Moving up a rung multiplies the evidence you need and opens a payer that did not exist below. The rung that matches your planner answer lights up.
Where European plans break
Ask these five questions in your first call with any US buyer. Their answers tell you whether a budget exists.
Glossary
Sources
Facts were checked against the pages below between 17 and 20 November 2026. Where a primary source could not be opened, the entry is a secondary summary. Fit ratings, the bottleneck gate and the 90-day order are editorial judgments by Newfund Heka.